Muscle Relaxant Drugs Market 2025-2029: Unveiling Growth Developments with the Latest Updates
Offering reliable and timely data, this report is a key resource for anyone building or refining their muscle relaxant drugs industry roadmap.
How Fast Is The Muscle Relaxant Drugs Market Growing Towards 2025?
The muscle relaxant drugs market size has grown strongly in recent years. It will grow from $4.77 billion in 2024 to $5.11 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to shift in treatment approaches, chronic pain management, pharmaceutical innovation in drug formulations, rise in surgical procedures, expansion in physical rehabilitation practices.
The muscle relaxant drugs market size is expected to see strong growth in the next few years. It will grow to $6.9 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to multidisciplinary pain management approaches, aging population and chronic conditions, research in targeted therapies, focus on non-pharmacological pain relief, advancements in pain management therapies. Major trends in the forecast period include advancements in side effect profiles, personalized medicine approach, research in alternative therapies, integration of muscle relaxants in pain management protocols, advent of botulinum toxin injections.
Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8751&type=smp
Muscle Relaxant Drugs Market Drivers And Opportunities
The rising geriatric population is expected to propel the growth of the muscle relaxant drugs market going forward. The geriatric population refers to older adults 65 years and beyond. Muscle relaxant drugs are used for sedating and reducing the pain of the geriatric population who are more likely to suffer from musculoskeletal disorders. For instance, in October 2022, according to the World Health Organization, a Switzerland-based international public health organization, the global population of individuals aged 60 years is projected to increase to 1.4 billion by 2022 compared to 1 billion in 2020. Moreover, 1 out of 6 people in the world will be aged more than 60 years or older by 2030. Therefore, the rising geriatric population is driving the growth of the muscle relaxant drugs market.
How Is The Muscle Relaxant Drugs Market Segmented?
The muscle relaxant drugs market covered in this report is segmented –
1) By Drug Type: Facial Muscle Relaxant Drugs, Skeletal Muscle Relaxant Drugs, Neuromuscular Blocking Agents
2) By Formulation: Cyclobenzaprine, Carisoprodol, Chlorzoxazone, Metaxalone, Methocarbamol, Baclofen, Tizanidine, Orphenadrine, Dantrolene
3) By Route Of Administration: Oral, Injectable, Spray, Ointment
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Facial Muscle Relaxant Drugs: Botulinum Toxin, Dysport, Xeomin
2) By Skeletal Muscle Relaxant Drugs: Centrally Acting Muscle Relaxants, Peripherally Acting Muscle Relaxants
3) By Neuromuscular Blocking Agents: Non-Depolarizing Agents, Depolarizing Agents
What Are The Key Trends And Market Opportunities In The Muscle Relaxant Drugs Sector?
Product innovations are the key trend gaining popularity in the muscle relaxant drug market going forward. Major companies operating in the market are developing innovative drugs for specific medical applications, such as generic versions of muscle relaxant drugs, muscle relaxants for animals, drugs that provide flexible, customized dosing, and others, to sustain their position in the market. For instance, in June 2022, Amneal Pharmaceuticals Inc., a US-based integrated specialty pharmaceutical company, launched LYVISPAH, a baclofen oral granule (5, 10, and 20 mg) specialty product approved by the US Food and Drug Administration for the treatment of spasticity associated with multiple sclerosis and other spinal cord disorders. LYVISPAHI offers flexible, customized dosing with 5 mg, 10 mg, and 20 mg single-dose packets of granules that are used in treating muscle stiffness, spasms, and pain from multiple sclerosis. The rapidly dissolving flavored granules offer an alternative for patients with spasticity who also have difficulty swallowing pills. The product can be administered in three ways: directly into the patient's mouth with or without water, mixed with liquids or foods, or through an enteral feeding tube.
Major Companies Operating In The Muscle Relaxant Drugs Market Are:
Major companies operating in the muscle relaxant drugs market are Pfizer Inc., Ipsen Pharma SA, Teijin Limited, Par Pharmaceutical Companies Inc., Orient Phaarma Co. Ltd., Novartis AG, Accord Healthcare Ltd., Amneal Pharmaceuticals LLC, Fresenius Kabi India Pvt. Ltd., Aurobindo Pharma Ltd., Mylan NV, Hikma Pharmaceuticals PLC, Akorn Incorporated, Merck & Co. Inc., Teva Pharmaceuticals Industries Ltd., Lifesciences Limited, Neurana Pharmaceuticals Inc., Dr. Reddy's Laboratories, Lannett Company Inc., Unichem Laboratories, SteriMax Inc., Endo Pharmaceuticals Inc., Abbvie Inc., Merz Pharmaceuticals LLC, Vertical Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Eisai Co. Ltd., Metacel Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Lupin Ltd., Intas Pharmaceuticals Ltd., Alkem Laboratories Ltd.
View the full muscle relaxant drugs market report here:
https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report
Regional Analysis: Opportunities And Challenges In The Muscle Relaxant Drugs Market
North America was the largest region in the muscle relaxant drugs market share in 2024. The regions covered in the muscle relaxant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
#Contact Us:#
The Business Research Company
https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
#Follow Us On:#
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment